IP Library Granted Patent US 10,717,813
Granted Patent B2
US 10,717,813 · App. 15/000,833 · Granted Jul 21, 2020

Photocrosslinkable poly(caprolactone fumarate)

Inventors: Shanfeng Wang (Knoxville, TN); Lichun Lu (Rochester, MN); Michael J. Yaszemski (Rochester, MN)
Assignee: Mayo Foundation for Medical Education and Research
C08G63/912A61L27/18A61L27/46A61L27/54A61L27/56C08G63/08C08L67/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,717,813
App. No.
15/000,833
Granted
Jul 21, 2020
Kind
B2
Abstract

Fumaric acid or a salt thereof, such as a fumaryl halide (e.g. fumaryl chloride), which contains unsaturated carbon-carbon double bonds that can be used for in situ crosslinking, is copolymerized with poly(caprolactone) diol in the presence of an alkali metal salt. The resulting photocrosslinkable biocompatible and bioresorbable poly(caprolactone fumarate) biomaterial is useful in the fabrication of injectable an in-situ hardening scaffolds for application in skeletal reconstruction.

Claims (19)

1. A photocrosslinkable, biodegradable composition comprising:

poly(caprolactone fumarate);

and a photoinitiator,

wherein the poly(caprolactone fumarate) is colorless or light colored, and clear in the melt state.

2. The composition of claim 1 , wherein the composition is injectable.

3. The composition of claim 1 , wherein the composition is an injectable bone substitute.

4. The composition of claim 1 , wherein, the composition is an injectable bone cement.

5. The composition of claim 1 , further comprising a porogen.

6. The composition of claim 1 , further comprising particulate or fiber reinforcement materials.

7. The composition of claim 1 , wherein the composition does not include a crosslinker.

8. The composition of claim 1 , wherein the photoinitiator is selected from the group consisting of benzoin and benzoin ether compounds, benzil ketal compounds, acetophenone compounds, aminoalkylphenone compounds, hydroxyalkylphenone compounds, acylphosphine oxides, acylphosphine sulfides, phenylglyoxylate compounds, benzophenone compounds, thioxanthone compounds, and mixtures thereof.

9. The composition of claim 1 , wherein the poly(caprolactone fumarate) is prepared by reacting (i) a poly(ε-caprolactone) diol, and (ii) fumaric acid or a salt thereof.

10. The composition of claim 1 , wherein the poly(caprolactone fumarate) is prepared by reacting (i) a poly(ε-caprolactone) diol, and (ii) fumaric acid or a salt thereof in the presence of an alkali metal salt.

11. The composition of claim 1 , wherein the poly(caprolactone fumarate) is prepared by reacting (i) a poly(ε-caprolactone) diol, and (ii) fumaric acid or a salt thereof in the presence of an alkali metal carbonate.

12. The composition of claim 1 , wherein the poly(caprolactone fumarate) is prepared by reacting (i) a poly(ε-caprolactone) diol, and (ii) fumaric acid or a salt thereof in the presence of potassium carbonate.

13. The composition of claim 1 , wherein the poly(caprolactone fumarate) is prepared by reacting (i) a poly(ε-caprolactone) diol, and (ii) a fumaryl halide.

14. The composition of claim 1 , wherein the poly(caprolactone fumarate) is prepared by reacting (i) a poly(ε-caprolactone) diol, and (ii) fumaryl chloride.

15. The composition of claim 1 , further comprising a bioactive agent selected from enzymes, organic catalysts, ribozymes, organometallics, proteins, glycoproteins, peptides, polyamino acids, antibodies, nucleic acids, steroidal molecules, antibiotics, antimycotics, cytokines, growth factors, carbohydrates, oleophobics, lipids, extracellular matrix and/or its individual components, pharmaceuticals, therapeutics and mixtures thereof.

16. The composition of claim 1 , wherein the copolymer was prepared by reacting (i) a poly(ε-caprolactone)diol and (ii) fumaric acid or a salt thereof in the presence of potassium carbonate to form a repeating polymer of polycaprolactone fumarate.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 19, 2020
From: WANG, SHANFENG; LU, LICHUN; YASZEMSKI, MICHAEL J.
To: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
Reel/Frame 052160/0683 →
CONFIRMATORY LICENSE Recorded Jun 27, 2016
From: MAYO CLINIC ROCHESTER
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 039167/0439 →
Continuity (3)
Division 11718906
Provisional Application 60627079 · Nov 12, 2004
Related Publication 20160199536A1 · Jul 14, 2016